Slingshot members are tracking this event:

GlycoMimetics to Present New Preclinical Data on GMI-1359 Dual Antagonist

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details An oral presentation and a poster at the AARC Annual Meetingwill highlight data on GMI-1359, a potent dual antagonist of both E-selectin and CXCR4, demonstrating anti-tumor activity in preclinical models of pancreatic cancer and acute myeloid leukemia (AML), respectively.  According to the VP, the "data provides additional preclinical support for initiating clinical trials of GMI-1359 in both FLT3 mutated AML and pancreatic cancer."
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 16, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Preclinical Data, Gmi-1359, Anti-tumor Activity, Pancreatic Cancer, Acute Myeloid Leukemia